CN115551515A - 靶向3CLpro的连翘苷及其衍生物和抗新冠应用 - Google Patents

靶向3CLpro的连翘苷及其衍生物和抗新冠应用 Download PDF

Info

Publication number
CN115551515A
CN115551515A CN202180005782.6A CN202180005782A CN115551515A CN 115551515 A CN115551515 A CN 115551515A CN 202180005782 A CN202180005782 A CN 202180005782A CN 115551515 A CN115551515 A CN 115551515A
Authority
CN
China
Prior art keywords
virus
covid
phillyrin
protein
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180005782.6A
Other languages
English (en)
Other versions
CN115551515B (zh
Inventor
杨子峰
富力
蒋革
钟南山
杨威
马钦海
惠敏
李楚芳
王硕
潘蔚倚
鲁岐
宋瑷瑷
侯集瑞
李润峰
鲁明明
王英平
柳洋
刘国友
付文斐
冯雪
周庆丰
衣小凤
林荣鑫
张羽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Fu Sheng Natural Pharmaceutical Development Co ltd
Original Assignee
Dalian Fu Sheng Natural Pharmaceutical Development Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Fu Sheng Natural Pharmaceutical Development Co ltd filed Critical Dalian Fu Sheng Natural Pharmaceutical Development Co ltd
Publication of CN115551515A publication Critical patent/CN115551515A/zh
Application granted granted Critical
Publication of CN115551515B publication Critical patent/CN115551515B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

靶向抑制COVID‑19病毒的3CLpro蛋白的连翘苷及其衍生物、连翘苷和连翘脂素的组合物在制备用于抗冠状病毒或用于治疗冠状病毒所致疾病的药物中的应用。其中，冠状病毒是COVID‑19病毒，冠状病毒所致疾病为COVID‑19。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN202180005782.6A 2020-03-09 2021-02-09 靶向3CLpro的连翘苷及其衍生物和抗新冠应用 Active CN115551515B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010155743.1A CN113368121A (zh) 2020-03-09 2020-03-09 抗冠状病毒的连翘苷和连翘脂素组合物
PCT/CN2021/076179 WO2021179878A1 (zh) 2020-03-09 2021-02-09 靶向3CLpro的连翘苷及其衍生物和抗新冠应用

Publications (2)

Publication Number Publication Date
CN115551515A true CN115551515A (zh) 2022-12-30
CN115551515B CN115551515B (zh) 2023-09-22

Family

ID=77569404

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010155743.1A Pending CN113368121A (zh) 2020-03-09 2020-03-09 抗冠状病毒的连翘苷和连翘脂素组合物
CN202180005782.6A Active CN115551515B (zh) 2020-03-09 2021-02-09 靶向3CLpro的连翘苷及其衍生物和抗新冠应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010155743.1A Pending CN113368121A (zh) 2020-03-09 2020-03-09 抗冠状病毒的连翘苷和连翘脂素组合物

Country Status (8)

Country Link
US (1) US20230101803A1 (zh)
EP (1) EP4119146A4 (zh)
JP (1) JP7430803B2 (zh)
CN (2) CN113368121A (zh)
BR (1) BR112022015046A2 (zh)
CA (1) CA3168457A1 (zh)
WO (1) WO2021179878A1 (zh)
ZA (1) ZA202211004B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368121A (zh) * 2020-03-09 2021-09-10 吉林亚泰制药股份有限公司 抗冠状病毒的连翘苷和连翘脂素组合物
CN116196321A (zh) * 2021-12-01 2023-06-02 盖鑫 双环氧木脂素化合物及组合物抗病毒的应用和制备

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105362283A (zh) * 2014-08-07 2016-03-02 富力 连翘苷/连翘脂素组合物在制备缓解或/和治疗病毒性疾病的药物或保健品中的应用
CN113368121A (zh) * 2020-03-09 2021-09-10 吉林亚泰制药股份有限公司 抗冠状病毒的连翘苷和连翘脂素组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2425476A (en) * 2004-02-27 2006-11-01 Phynova Ltd Multi-herb medicament for the treatment of SARS
CN104650108B (zh) * 2013-11-18 2017-05-24 富力 连翘脂素硫酸酯及其衍生物、制备方法及其应用
CN105461731B (zh) * 2014-08-07 2017-05-24 富力 连翘脂素布洛芬酯、其制备及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105362283A (zh) * 2014-08-07 2016-03-02 富力 连翘苷/连翘脂素组合物在制备缓解或/和治疗病毒性疾病的药物或保健品中的应用
CN113368121A (zh) * 2020-03-09 2021-09-10 吉林亚泰制药股份有限公司 抗冠状病毒的连翘苷和连翘脂素组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HAI-XIA SU等: "Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients", 《ACTA PHARMACOLOGICA SINICA》, vol. 41, pages 1167 - 1177, XP037234418, DOI: 10.1038/s41401-020-0483-6 *
JIU-WANG YU等: "Exploring the active compounds of traditional Mongolian medicine in intervention of novel coronavirus (COVID-19) based on molecular docking method", 《JOURNAL OF FUNCTIONAL FOODS》, vol. 71, pages 1 - 10 *

Also Published As

Publication number Publication date
CA3168457A1 (en) 2021-09-16
JP2023510015A (ja) 2023-03-10
EP4119146A1 (en) 2023-01-18
CN113368121A (zh) 2021-09-10
BR112022015046A2 (pt) 2022-09-20
EP4119146A4 (en) 2024-04-10
US20230101803A1 (en) 2023-03-30
CN115551515B (zh) 2023-09-22
WO2021179878A1 (zh) 2021-09-16
JP7430803B2 (ja) 2024-02-13
ZA202211004B (en) 2024-02-28

Similar Documents

Publication Publication Date Title
Cao et al. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence
Wen et al. Synergistic effect of Zanamivir− Porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus
Chidambaram et al. In silico molecular docking: Evaluation of coumarin based derivatives against SARS-CoV-2
CN115551515B (zh) 靶向3CLpro的连翘苷及其衍生物和抗新冠应用
TW201404785A (zh) 升糖素類似物
CN103476933B (zh) 白介素1受体的拮抗剂
KR20190101990A (ko) 펩티드 wkdeagkplvk를 포함하는 조성물
EP4233888A2 (en) Modified protein
US20150218214A1 (en) Peptide and the use thereof
JP2023515603A (ja) 可溶性ａｃｅ２及び融合タンパク質、並びにその適用
Giri et al. Battle against Coronavirus: Repurposing old friends (Food borne polyphenols) for new enemy (COVID-19)
Velayutham et al. Antiproliferation of MP12 derived from a fungus, Aphanomyces invadans virulence factor, cysteine-rich trypsin inhibitor on human laryngeal epithelial cells, and in vivo zebrafish embryo model
Anakha et al. Human arginase 1, a Jack of all trades?
CN112402402A (zh) 一种黄腐酚在制备新型冠状病毒抑制剂中的应用
RU2804307C1 (ru) Филлирин и его производные для подавления белка 3clpro и борьбы с вирусом covid-19
Minegaki et al. The C-terminal penta-peptide repeats of major royal jelly protein 3 ameliorate the progression of inflammation in vivo and in vitro
Adedayo et al. In-silico studies of Momordica charantia extracts as potential candidates against SARS-CoV-2 targeting human main protease enzyme (Mpro)
JP2016526533A (ja) アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体
CN114668843A (zh) 一种纳米自组装糖肽biva-pk及其在缺血再灌注损伤导致的肾脏纤维化中的应用
CN113501862A (zh) 一种多肽及其在制备免疫调节药物中的应用
Mahajan et al. Microbial iron chelators: a possible adjuncts for therapeutic treatment of SARS-CoV-2 like viruses
Gonzatti et al. Mechanism of molecular interaction of sitagliptin with human DPP4 enzyme-New Insights
Raphael et al. In silico evaluation on the inhibition efficacy of five antivirals on SARS-CoV-2 protease (COVID-19)
WO2021195883A1 (zh) TFF2蛋白和IFN-κ蛋白联用在治疗新型冠状病毒感染中的应用
WO2021238761A1 (en) Therapeutic composition and method for treating coronavirus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant